Li, Shuqiang
Sun, Jing
Allesøe, Rosa
Datta, Krishnalekha
Bao, Yun
Oliveira, Giacomo
Forman, Juliet
Jin, Roger
Olsen, Lars Rønn
Keskin, Derin B.
Shukla, Sachet A.
Wu, Catherine J.
Livak, Kenneth J. http://orcid.org/0000-0001-9105-5856
Article History
Received: 27 November 2018
Accepted: 7 May 2019
First Online: 24 July 2019
Competing interests
: J.S. is currently an employee of Moderna Therapeutics. K.D. is an employee of IDT; Y.B. was an employee of IDT during the time of this work; K.J.L. was a paid consultant of IDT during a portion of this work; D.B.K. has previously advised Neon Therapeutics and owns equity in Aduro Biotech, Agenus Inc., Ampliphi BioSciences Corp., Biomarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Celldex Therapeutics Inc., Editas Medicine Inc., Exelixis Inc., Gilead Sciences Inc., IMV Inc., Lexicon Pharmaceuticals Inc., Sangamo Therapeutics, and Stemline Therapeutics Inc.; C.J.W. is a founder of Neon Therapeutics and a member of its scientific advisory board. C.J.W. is subject to a conflict of interest management plan for the reported studies because of her competing financial interests in Neon Therapeutics. Under this plan, C.J.W. may not access identifiable human subjects data nor otherwise participate directly in the IRB-approved protocol reported herein. C.J.W.’s contributions to the overall program strategy and data analyses occurred on a de-identified basis. The remaining authors declare no competing interests.